GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » Capital Expenditure

NVN Liquidation (NVN Liquidation) Capital Expenditure : $-3.37 Mil (TTM As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

NVN Liquidation's cash flow for capital expenditures for the three months ended in Mar. 2023 was $-0.02 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.37 Mil.


NVN Liquidation Capital Expenditure Historical Data

The historical data trend for NVN Liquidation's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation Capital Expenditure Chart

NVN Liquidation Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -1.11 -0.42 -0.65 -9.05 -4.27

NVN Liquidation Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -1.87 -0.41 -1.07 -0.02

NVN Liquidation Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NVN Liquidation (NVN Liquidation) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 64, Pittsboro, NC, USA, 27312
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman director 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour director C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay officer: VP, Finance & Corp. Controller C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John officer: EVP, Chief Operating Officer C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky director TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin director C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram director 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer director 7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak officer: Chief Accounting Officer C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513